Completely resected NSCLC(non-squamous cell carcinoma, stage II - IIIA)
Conditions
Interventions
Dose:day1 CDDP 75mg/m2+PEM 500 mg/m2 with short hydration Cycle: 4 cycles
Sponsors
Division of Respiratory Medicine, Department of Internal Medicine,Kobe University Graduate School of Medicine
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: (1)The patient histologically proven as non-small cell lung cancer (2)The patient with p-staged II - IIIA that received segmentectomy, lobectomy, or bi-lobectomy (3) Performance Status is 0 - 1 (ECOG). (4) 20 years of age or older, 75 years of age or younger. (5) The patient who does not receive any chemotherapy, radiotherapy, or immunotherapy prior to resection (6) The patient who preserves the main organ ( the bone marrow, liver, kidney and so on ) (7) The patient who can receive chemotherapy within 4 - 8 weeks after resection (8) The patient who gives written informed consent
Exclusion criteria
Exclusion criteria: (1)The patient with infection (2)The patient with fever (equal to or more than 38 C) (3)The patient with heavy complication (4)The patient with active double-cancer (5)The patient with uncontrolled pleural effuson (6)The patient with a motor-palsy or figure of peripheral-nerve-disease (7)The patient with drug hypersensitivity (8)The patient with common use of NSAIDs (9)The expectant mother, the woman who has a lactating-woman and the possibility of the pregnancy (10)The patient judged as unsuitable by the doctor
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Chemotherapy compliance in the four cycles | — |
Secondary
| Measure | Time frame |
|---|---|
| 1.safety 2.extraction rate from hospitalization to outpatient clinic 3.2-years disease free survival | — |
Countries
Japan
Contacts
Public ContactMotoko Tachihara
Kobe University Graduate School of Medicine Division of Respiratory Medicine, Department of Internal Medicine,
Outcome results
None listed